COMMUNIQUÉS West-GlobeNewswire

Takeda termine son acquisition de TiGenix suite à l'expiration de la période de retrait
31/07/2018
COMMUNIQUÉ DE PRESSE Takeda termine son acquisition de TiGenix suite à l'expiration de la période de retrait TiGenix devient donc une filiale propriété exclusive de Takeda Les Actions ordinaires ont été radiées d' [...]
Sanofi: Q2 2018 Performance Positions Sanofi for New Growth Phase
31/07/2018
Paris, July 31, 2018 Q2 2018 Performance Positions Sanofi for New Growth Phase Q2 2018 Change Change at CER H1 2018 Change Change at CER IFRS net sales reported €8,176m -5.7% +0.1% €16,074m -7.2% -0.1% IFRS net income [...]
Sanofi : Après les résultats du T2 2018, Sanofi bien placé pour une nouvelle période de croissance
31/07/2018
Paris, le 31 juillet 2018 Après les résultats du T2 2018, Sanofi bien placé pour une nouvelle période de croissance T2 2018 Variation Variation à TCC S1 2018 Variation Variation à TCC Chiffre d'affaires net IFRS publié [...]
Zealand announces an 85% increase in Soliqua® 100/33/ Suliqua® royalty revenue from first to second quarter of 2018
31/07/2018
Company announcement - No. 19/2018 Zealand announces an 85% increase in Soliqua ® 100/33/ Suliqua® royalty revenue from first to second quarter of 2018 Net sales of Soliqua ® 100/33/ Suliqua® and Lyxumia®/Adlyxin® of [...]
Eckert & Ziegler BEBIG: First Half-Year Results 2018 Published
31/07/2018
Seneffe - Belgium, July 31, 2018, Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB) has announced today its half-year results 2018. The report including a selection of consolidated key [...]
Eckert & Ziegler BEBIG: Publication du résultat du premier semestre 2018
31/07/2018
Seneffe - Belgique, 31 juillet 2018, Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB) a communiqué aujourd'hui son rapport du 1er semestre 2018. Le rapport qui comprend une sélection de [...]
ObsEva SA to Hold Second Quarter 2018 Financial Results and Business Update Call on August 8, 2018
31/07/2018
Geneva, Switzerland and Boston, MA - July 31, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for [...]
MDxHealth: SelectMDx Study Demonstrates Cost-effectiveness in US Healthcare System
31/07/2018
NEWS RELEASE REGULATED INFORMATION Data published in Journal of Urology reports over $500 million in potential annual cost savings for the US healthcare system IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, July 31, [...]
MDxHealth (R) : Une étude démontre la rentabilité du test SelectMDx au sein du système de soins de santé américain
31/07/2018
COMMUNIQUÉ DE PRESSE INFORMATIONS RÉGLEMENTÉES Les données publiées dans la revue Journal of Urology indiquent que le système des soins de santé américain pourrait, chaque année, économiser plus de 500 millions de [...]
Fagron NV : Disclosure of received notification
31/07/2018
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 31 July 2018 - 7:00am (CET) Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron [...]
Biocartis Group NV: Study Abstract on Performance of Idylla(TM) RAS tests Selected for Oral Presentation at 70th AACC Annual Scientific Meeting in Chicago, IL (US)
31/07/2018
PRESS RELEASE : 31 July 2018, 07:00 CEST/14:00 CDT Study Abstract on Performance of Idylla(TM) RAS tests Selected for Oral Presentation at 70th AACC Annual Scientific Meeting in Chicago, IL (US) Mechelen, Belgium, 31 [...]
Progenics Pharmaceuticals Announces FDA Approval for AZEDRA® (iobenguane I 131) to Treat Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma
31/07/2018
The First FDA-Approved Treatment for These Rare, Life-Threatening Neuroendocrine Cancers in Patients Aged 12 and Older Company to Host Conference Call Tomorrow at 8:00 AM ET NEW YORK, July 30, 2018 (GLOBE NEWSWIRE) -- [...]
Immutep’s LAG-3 Immunostimulant Product Candidate, Efti, Receives IND Approval From U.S. FDA
31/07/2018
On schedule to initiate the TACTI-002 Phase II clinical study in 2H 2018 SYDNEY, Australia, July 30, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”) is pleased to announce [...]
MacroGenics Announces Date of Second Quarter 2018 Financial Results Conference Call
31/07/2018
ROCKVILLE, MD, July 30, 2018 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Tuesday, August 7, 2018, the Company will release its financial results for the quarter ended June 30, 2018. [...]
Cannabix Technologies Comments on Bill C-46 – Unaware of any Material Change
31/07/2018
The Cannabix Marijuana Breathalyzer is being developed to provide law enforcement and employers a tool to enforce public safety. VANCOUVER, British Columbia, July 30, 2018 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc [...]
ChemioCare Announces Addition of Three Experienced Team Members
31/07/2018
NEW YORK, July 30, 2018 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a biotech company focused on transforming chemotherapy induced nausea and vomiting (CINV) outcomes through transdermal [...]
CreekView Health Center Named Great Place to Work
30/07/2018
PLEASANTON, Calif., July 30, 2018 (GLOBE NEWSWIRE) -- CreekView Health Center in Pleasanton, California, has been certified as a top workplace by the independent research and consulting firm Great Place to Work ®. Great [...]
MPX Postpones Filing Date of 2018 Annual Statements
30/07/2018
Company to reschedule conference call with shareholders upon finalization of financial results TORONTO, July 30, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“ MPX ” or the “ Company ”) (CSE: MPX; OTC: MPXEF) [...]
Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine prevention
30/07/2018
Patients on Aimovig (erenumab) in clinical trials reported consistent and sustained migraine prevention, with many experiencing a 50% or more reduction in monthly migraine days; safety and tolerability were similar to [...]

Pages